Spring Bank Pharmaceuticals, Inc. announced that it has entered into a research agreement with the University of Texas Southwestern Medical School (UTSW) to evaluate Spring Bank's novel small molecule STING antagonist compounds. Spring Bank has entered into a collaborative research agreement with the University of Texas Southwestern Medical Center for the evaluation of Spring Bank's STimulator of INterferon Gene (STING) antagonist compounds. Dr. Nan Yan, as Principal Investigator, will evaluate Spring Bank's STING antagonist compounds in autoimmune disease models. Spring Bank is designing its STING antagonist compounds to block aberrant STING-dependent signaling by a novel mechanism of action. These compounds are being developed to have therapeutic utility in certain autoimmune diseases, including various interferonopathies.